Benzodiazepine use among older adults is common despite evidence for many potential risks. While treatment guidelines recommend short-term use of benzodiazepines, up to one-third of use is long term, which is most common among older adults. To reduce benzodiazepine prescribing to older adults, one potential point for intervention is at the transition from new to long-term use, yet little is known about the factors that predict conversion to long-term use.
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Methods | We evaluated transition to long-term benzodiazepine use among older adults newly prescribed this drug (n = 576) by a nonpsychiatric clinician from 2008 to 2016 within Pennsylvania's prescription assistance program for lowincome older adults. Patients newly prescribed a benzodiazepine (ie, those with no use in the past year) were contacted for clinical assessment by a telephone-based behavioral health service (Supporting Seniors Receiving Treatment and Intervention [SUSTAIN] ). 4 The initial assessment included screening instruments assessing for depression, anxiety, sleep quality, and pain. Long-term benzodiazepine use was defined as a medication possession ratio (MPR) greater than 30% in the year following the initial prescription. Logistic regression was used to determine patient sociodemographic and clinical characteristics associated with long-term benzodiazepine use. After completing the clinical interview, participants provided verbal consent to allow the use of clinical data for research purposes in accordance with a University of Pennsylvania Institutional Review Board-approved protocol. Analyses were conducted using SAS statistical software, version 9.4 (SAS Institute Inc).
Results | The mean (SD) age of adults newly prescribed a benzodiazepine was 78.4 (7.0) years ( For sensitivity analyses, we completed adjusted models predicting 3 alternative long-term benzodiazepine use outcomes at 1 year, whether the patient (1) was prescribed at least 1 benzodiazepine refill (white race and days supplied were significant), (2) had a benzodiazepine prescription 1 year after index date (ie, on day 366; days supplied were significant); and (3) MPR as a continuous measure (white race and days supplied were significant).
Discussion | In this sample of older adults newly prescribed a benzodiazepine by a nonpsychiatric clinician, nearly onethird of patients went on to long-term use. While treatment guidelines recommend only short-term prescribing, if any, these long-term patients were prescribed nearly 8 months' worth of benzodiazepine. Of the clinical measures evaluated, only poor sleep quality was associated with the likelihood of continued benzodiazepine use in adjusted analyses. White patient race and a larger initial prescription were also associated with conversion to long-term use. It is a cause for concern that these nonclinical factors are associated with benzodiazepine prescribing, which suggests that approaches to reduce prescribing of this drug that focus on specific clinical populations may have limited success.
Among our study's limitations, it does not account for asneeded medication use, which may have an effect on our calculation of long-term use. The analysis is limited to lowincome older adults from Pennsylvania, which may limit generalizability. Definitions of long-term benzodiazepine use vary, 5 and it is possible that a different classification of longterm use might have yielded different results. However, we used 3 alternative definitions with no significant variation in our findings.
In conclusion, for new benzodiazepine users, prescribers should "begin with the end in mind" and immediately engage patients in discussion regarding the expected (brief) length of treatment, particularly when prescribed for insomnia. In light of the continued growth of psychotropic prescribing to older adults by nonpsychiatric clinicians, it is critical to improve access to and education regarding nonpharmacologic treatment so clinicians feel they have treatment alternatives to offer. additional SD (ie, 9.7 days). So for each additional 9.7 days of benzodiazepine prescribed in the index prescription, the odds of long-term were 1.98-fold higher.
